Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s ...

Jay Bradner, M.D., has revealed that Novartis has scrapped one-fifth of its drug programs. The cull is designed to limit Novartis’ pipeline to potentially transformative therapies that fit with the ...

EAST HANOVER, N.J., July 12, 2023 /PRNewswire/ -- Novartis and the Novartis US Foundation proudly announce the significant expansion of Beacon of Hope, our 10-year commitment to co-create programs ...

The collaboration agreement joins Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s expertise in immuno-dermatology to identify, validate, and ...

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development of the DP2 antagonist in asthma. The setback means Amgen, AstraZeneca ...

EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ -- Novartis is inviting patient advocacy organizations to submit proposals for programs that offer to expand and improve understanding of biomarker ...

Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...

Novartis Pharmaceuticals Corp. on Wednesday became the second company to launch a prescription discount program for low-income elderly Americans, but analysts said it would not lower costs enough for ...

Advarra, Virb and BeeKeeperAI sign on to Beacon of Hope to provide suite of digital tools to facilitate clinical trials and research on healthcare inequities at Historically Black Medical School ...